Cantor Fitzgerald, L. P. Compass Therapeutics, Inc. Transaction History
Cantor Fitzgerald, L. P.
- $4.65 Billion
- Q1 2025
A detailed history of Cantor Fitzgerald, L. P. transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Cantor Fitzgerald, L. P. holds 150,000 shares of CMPX stock, worth $376,499. This represents 0.01% of its overall portfolio holdings.
Number of Shares
150,000
Previous 100,000
50.0%
Holding current value
$376,499
Previous $145,000
96.55%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding CMPX
# of Institutions
127Shares Held
101MCall Options Held
2.52MPut Options Held
3.1M-
Orbimed Advisors LLC San Diego, CA22.4MShares$56.1 Million1.32% of portfolio
-
Tang Capital Management LLC San Diego, CA11.1MShares$27.7 Million1.36% of portfolio
-
Blackstone Inc New York, NY10MShares$25.2 Million0.09% of portfolio
-
Bio Impact Capital LLC Cambridge, MA8.44MShares$21.2 Million2.97% of portfolio
-
Black Rock Inc. New York, NY6.61MShares$16.6 Million0.0% of portfolio
About Compass Therapeutics, Inc.
- Ticker CMPX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 101,285,000
- Market Cap $254M
- Description
- Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...